IGA | Jotup

Tuebora Launches “Ask Tuebora”, a Generative AI Tool for Identity and Access Management

Retrieved on:

Thursday, January 25, 2024

Data Management, Security, Apps, Applications, Technology, Software, Artificial Intelligence, Internet, IGA, Organization, Identity management, Cognition, IAM, Medical device

Tuebora, a leading provider of knowledgeable and interactive Identity Governance Administration (IGA) solutions, announced today the availability of Ask Tuebora, a natural language query engine designed to simplify complex workflows and automate repetitive Identity Access Management (IAM) tasks.

Key Points:

Tuebora, a leading provider of knowledgeable and interactive Identity Governance Administration (IGA) solutions, announced today the availability of Ask Tuebora, a natural language query engine designed to simplify complex workflows and automate repetitive Identity Access Management (IAM) tasks.
Ask Tuebora is a generative AI tool that simulates human interaction and adapts its functionality to align with user thought processes, incorporating feedback and improving cognition with each query.
Ask Tuebora eliminates the need to learn specific system vendor terminology or multiple user interfaces.
Trial participants will be given a sample data set to explore how generative AI could be used in their organizations.

Stack Identity Expands Identity Access Risk Management Platform with Launch of Identity Threat Detection Response Capabilities

Retrieved on:

Wednesday, January 24, 2024

Stack Identity , a Silicon Valley-based company pioneering identity security, today announced the expansion of the Identity Access Risk Management Platform with identity threat detection and response (ITDR) to tackle shadow access and shadow identities.

Key Points:

Stack Identity , a Silicon Valley-based company pioneering identity security, today announced the expansion of the Identity Access Risk Management Platform with identity threat detection and response (ITDR) to tackle shadow access and shadow identities.
Stack Identity’s platform is powered by the industry’s first identity security data lake, which consolidates, correlates and contextualizes identity access risks and vulnerabilities across cloud and data estates.
“By leveraging the power of AI, our platform generates intelligent resolutions to effectively tackle identity access risks,” says Venkat Raghavan, CEO and founder of Stack Identity.
Enterprises already have a myriad of tools to tell them how bad things are, but Stack Identity excels in constructing a reliable path to remediate and govern identity threats.”
To access the Identity Access Risk Management Platform, visit https://stackidentity.com/identity-access-risk-platform .

LEO Pharma Announces Positive Phase 3 Head-to-head Data Results from DELTA FORCE Trial Comparing Delgocitinib Cream With Alitretinoin Capsules in Adults With Severe Chronic Hand Eczema (CHE)

Retrieved on:

Wednesday, January 24, 2024

Biotechnology, Pharmaceutical, Health, Clinical Trials, IGA, Hope, Delgocitinib, Patient, DLQI, CHE, Alitretinoin, Aes, Safety, Dermatology Life Quality Index, LEO, Leo Pharma, Quality of life (healthcare), Pharmaceutical industry

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the DELTA FORCE trial.

Key Points:

LEO Pharma A/S, a global leader in medical dermatology, today announced positive results from the DELTA FORCE trial.
Delgocitinib cream achieved the primary outcome measure of the trial by demonstrating a superior reduction in Hand Eczema Severity Index (HECSI) score from baseline to Week 12 compared to alitretinoin capsules.
Furthermore, patients receiving delgocitinib cream had a lower number of treatment-emergent adverse events (AEs) compared to those receiving alitretinoin capsules.
Detailed results from DELTA FORCE are planned to be submitted for scientific presentation and publication at a later date.

Radiant Logic Announces RadiantOne AI, with New Generative AI Data Assistant “AIDA”

Retrieved on:

Thursday, January 11, 2024

Security, Data Management, Technology, Artificial Intelligence, Software, IGA, Radiant, Artificial intelligence, Data management, Radiant Logic, Fatigue, IAM, Language, Risk, UAR, AIDA, Organization, Data, Medical device

Radiant Logic, the Identity Data Fabric company, today unveiled RadiantOne AI , its data lake powered Artificial Intelligence engine, and AIDA, its Generative AI Data Assistant.

Key Points:

Radiant Logic, the Identity Data Fabric company, today unveiled RadiantOne AI , its data lake powered Artificial Intelligence engine, and AIDA, its Generative AI Data Assistant.
RadiantOne AI is designed to complement your existing tech stack and governance products by correlating data across multiple sources and providing contextual information to drive better decision making.
The first capability to be unveiled on RadiantOne AI is a truly automated user access review (UAR) process, expertly guided by AIDA.
Sign up here to be added to the exclusive wait list for RadiantOne AI.

Metcash Digital Transformation Strategy Analysis Report 2023: Technology Focus, Initiatives, Partnership Network Map, ICT Budget, and Contracts - ResearchAndMarkets.com

Retrieved on:

Wednesday, January 10, 2024

Supply Chain Management, Marketing, Other Retail, Retail, Communications, IGA, Bottle, Food industry, Metcash, Supermarket, Home Hardware, Food

This report provides insights into Metcash's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.

Key Points:

This report provides insights into Metcash's tech activities, including its digital transformation strategies, its innovation programs, and its technology initiatives.
Metcash is a wholesale distribution and marketing company that services a wide network of bannered independent retailers and wholesale customers in Australia and New Zealand.
In the liquor industry, Metcash supplies liquor to independently owned retailers operating under the Cellarbrations, IGA Liquor, and The Bottle-O brands.
In the hardware industry, Metcash services independent retailers operating under the Mitre 10, Home Hardware, Total Tools, and Hardings Hardware brands.

SEIU Local 2: National solidarity actions for striking Sobeys workers a huge success

Retrieved on:

Monday, December 18, 2023

Committee, Kate Beaton, MP, Eisner Awards, Union, Holiday, Farm Boy, El Jones, Agriculture, Thrifty Foods, IGA, Safeway, Christmas, Pressure, FreshCo, Film industry

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Over a dozen solidarity actions took place on Saturday to support workers on strike at Sobeys-owned Pete’s Frootique in Halifax.

Key Points:

TORONTO, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Over a dozen solidarity actions took place on Saturday to support workers on strike at Sobeys-owned Pete’s Frootique in Halifax.
Supporters asked the public not to shop at Sobeys or its subsidiaries during the holidays – not until Sobeys offers the striking workers a fair wage.
“The public support has been phenomenal”, said Nicholas Cook, one of the striking workers.
For information about the workers’ efforts to win a fair contract from Sobeys, owners of Pete’s Frootique, visit www.PetesOnStrike.ca .

FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older

Retrieved on:

Friday, December 15, 2023

Scalp, EST, Seborrhoeic dermatitis, Quality of life, Food, FAAD, Dermatology, Dermatitis, FDA, Success, Itch, Eyelid, Disease, Nose, Social stigma, NDA, MBA, MD, Doctor of Philosophy, Study, Inflammation, Eyebrow, Red, Gel, Week, IGA, Skin, Sleep, Face, Webcast, Human, Patient, Safety, PAP, Pharmaceutical industry

ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.

Key Points:

ZORYVE is a once-daily steroid-free foam and the first drug approved for seborrheic dermatitis with a new mechanism of action in over two decades.
“Approximately 10 million people in the United States have seborrheic dermatitis, but until today, there have been limited treatment options.
In Trial 203, 73% of individuals treated with ZORYVE foam achieved IGA Success (73.1% ZORYVE foam vs 40.8% vehicle; P
ZORYVE foam was well-tolerated with a favorable safety and tolerability profile during up to 52 weeks of treatment.

Xalient acquires Grabowsky, a leading digital identity specialist in Europe, accelerating its global leadership position

Retrieved on:

Thursday, December 14, 2023

CIAM, Trust, PAM, Acquisition, IAM, IGA, Organization, Mobile phone

LONDON, UK, 14th December 2023 – Global identity and access management (IAM), security, and network transformation specialist Xalient is pleased to announce its acquisition of Grabowsky BV, a leading digital identity advisory and managed services business based in Benelux.

Key Points:

LONDON, UK, 14th December 2023 – Global identity and access management (IAM), security, and network transformation specialist Xalient is pleased to announce its acquisition of Grabowsky BV, a leading digital identity advisory and managed services business based in Benelux.
This follows the recent acquisition of Integral Partners LLC in the USA, which has greatly strengthened Xalient’s position as a leading provider of IAM services and solutions worldwide.
The acquisition of Grabowsky combined with Integral Partners will accelerate Xalient’s position in the digital identity space, enriching its existing offer to customers and enabling Xalient to drive value for organizations worldwide.
Xalient is now uniquely positioned to provide its clients with a comprehensive global IAM service because of its unmatched identity expertise in the US, UK, and now the Benelux region.

ASLAN Pharmaceuticals Provides Year-End Update on Its Eblasakimab and Farudodstat Programs

Retrieved on:

Tuesday, December 12, 2023

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.

Key Points:

SAN MATEO, Calif. and SINGAPORE, Dec. 12, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals Ltd. (Nasdaq: ASLN), a clinical-stage, immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today provided a business update and updates related to its programs, eblasakimab and farudodstat.
“Throughout 2023, ASLAN made major progress on multiple fronts – advancing both of our lead programs, eblasakimab and farudodstat in Phase 2 testing, and establishing business development collaborations to further the development and utilization of eblasakimab,” said Dr Carl Firth, Chief Executive Officer, ASLAN Pharmaceuticals.
ASLAN will provide an update in early 2024 on the timing of the expected topline readout from the study in 2024.
Publication and presentation of further data from the TREK-AD study of eblasakimab, including biomarker data, and on farudodstat at major congresses.

Connect Biopharma Announces Positive Long-Term Data from the China Pivotal Trial of Rademikibart in Patients with Moderate-to-Severe Atopic Dermatitis

Retrieved on:

Tuesday, November 21, 2023

Patient, Entrepreneurship, Stage 2, CNTB, SAN, Simcere Pharmaceutical, Week, IGA, Safety, Pharmaceutical industry

These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.

Key Points:

These results follow the previously reported Stage 1 results of the trial, which met all primary and key secondary endpoints.
“This study demonstrated that rademikibart has a best-in-class potential, and if approved as a Q4W treatment, we believe could offer patients with AD a highly efficacious treatment with less frequent dosing than current approved treatments.
I’d like to thank the patients, their families, the clinical and manufacturing teams, and all of our vendors that were an integral part of this trial.
Patients that did not achieve EASI-50 (non-responders) were assigned to an open label Q2W rademikibart arm (n=86).